Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Quetiapine vs Seroquel in Schizophrenia, Bipolar Disorder, and Healthy Subjects
NCT03872596Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of quetiapine (extended-release tablet, brand name: Bipresso) in schizophrenia and bipolar disorder (BD) (5 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve to Last Observable Concentration and 1 more. Started Mar 2019; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT03872596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872596.